Ligand Pharmaceuticals Incorporated (LGND) Q3 2009 Earnings Results

Ligand Pharmaceuticals Beats on EPS, Stock Up 15.06%

Ligand Pharmaceuticals reported a small earnings per share of $0.01, exceeding expectations significantly. The stock reacted positively, rising by 15.06%, likely driven by the unexpected EPS surprise. Investors may view this as a sign of resilience despite the lack of revenue data and guidance.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$0.01	N/A	+120.00%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Cautiously Optimistic

Overall, management conveyed a sense of cautious optimism regarding the company's performance. They emphasized their commitment to improving financial metrics.

Management expressed satisfaction with the positive EPS surprise.

They highlighted ongoing efforts to enhance operational efficiency.

Ligand Pharmaceuticals Beats on EPS, Stock Up 15.06%

Key numbers

Management commentary

Ligand Pharmaceuticals Incorporated

More earnings this week

Ligand Pharmaceuticals Beats on EPS, Stock Up 15.06%

Key numbers

Management commentary